News

Charité Research Organisation GmbH has experience in the conduct of early phase projects for new anti-obesity drugs. We want to share our expertise in this special Whitepaper that comes in three parts. 

Many new drug candidates for obesity and related diseases are on the horizon, which are discussed according to their development phase in these Whitepapers.

In Part 2, the key drivers in the pathophysiology of non-alcoholic fat liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) and the recommended diagnostic tools to be used in clinical trials will be discussed. The recently approved THR-ß agonist Resmetirom and other pharmacological approaches for the treatment of NAFLD/NASH with or without obesity will be presented. Most of these are targeting metabolic dysregulation and intrahepatic lipotoxicity or inflammation. Other strategies include modification of genetic risk factors or activation of inflammatory immune cells.

Author and Contact:
Claudia Werner, MD, PhD
Charité Research Organisation GmbH
Charitéplatz 1, 10117 Berlin
claudia.werner@charite-research.org